Samuel K. Kulp

6.1k total citations
120 papers, 4.4k citations indexed

About

Samuel K. Kulp is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Samuel K. Kulp has authored 120 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 32 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Samuel K. Kulp's work include Histone Deacetylase Inhibitors Research (20 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and Research in Cotton Cultivation (9 papers). Samuel K. Kulp is often cited by papers focused on Histone Deacetylase Inhibitors Research (20 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and Research in Cotton Cultivation (9 papers). Samuel K. Kulp collaborates with scholars based in United States, Taiwan and China. Samuel K. Kulp's co-authors include Ching‐Shih Chen, Ching-Shih Chen, Dasheng Wang, Jing‐Ru Weng, Shuo Wei, Ya-Ting Yang, Charles L. Shapiro, Chung-Wai Shiau, Jui-Wen Huang and Kuen‐Feng Chen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Samuel K. Kulp

115 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samuel K. Kulp United States 40 2.8k 1.0k 738 499 408 120 4.4k
Matthias Ocker Germany 39 2.9k 1.0× 1.1k 1.0× 626 0.8× 419 0.8× 574 1.4× 161 5.0k
A. Ivana Scovassi Italy 38 3.5k 1.3× 1.6k 1.5× 582 0.8× 415 0.8× 499 1.2× 139 5.4k
Haiying Chen United States 31 2.7k 1.0× 1.0k 1.0× 764 1.0× 670 1.3× 275 0.7× 129 4.8k
Toshiaki Hayashi Japan 40 3.3k 1.2× 1.2k 1.2× 481 0.7× 313 0.6× 530 1.3× 194 5.9k
Daniela Trisciuoglio Italy 35 2.9k 1.0× 1.1k 1.0× 951 1.3× 355 0.7× 419 1.0× 88 4.4k
Ramzi M. Mohammad United States 41 2.9k 1.0× 1.2k 1.2× 601 0.8× 280 0.6× 216 0.5× 154 4.8k
Angela Nebbioso Italy 41 4.0k 1.4× 840 0.8× 482 0.7× 678 1.4× 565 1.4× 127 6.0k
Sibaji Sarkar United States 19 2.5k 0.9× 1.1k 1.1× 818 1.1× 309 0.6× 181 0.4× 47 4.0k
Xinliang Mao China 41 2.7k 1.0× 847 0.8× 534 0.7× 259 0.5× 349 0.9× 151 4.1k
William N. Hait United States 38 2.8k 1.0× 2.0k 1.9× 691 0.9× 241 0.5× 474 1.2× 92 4.8k

Countries citing papers authored by Samuel K. Kulp

Since Specialization
Citations

This map shows the geographic impact of Samuel K. Kulp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel K. Kulp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel K. Kulp more than expected).

Fields of papers citing papers by Samuel K. Kulp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel K. Kulp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel K. Kulp. The network helps show where Samuel K. Kulp may publish in the future.

Co-authorship network of co-authors of Samuel K. Kulp

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel K. Kulp. A scholar is included among the top collaborators of Samuel K. Kulp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel K. Kulp. Samuel K. Kulp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vu, Trang T., Justin Thomas, Zhiliang Xie, et al.. (2025). Intramuscular CMT‐167 Tumours Produce a Mild Cachexia Phenotype in C57BL/6J Mice. PubMed. 8(1).
2.
Xing, Enming, Anees M. Dauki, Hanna S. Radomska, et al.. (2023). SAT021 Development Of Niclosamide Analogs For Treatment Of Androgen Receptor Positive Hepatocellular Carcinoma. Journal of the Endocrine Society. 7(Supplement_1). 1 indexed citations
3.
Guo, Yizhen, Justin Thomas, Samuel K. Kulp, et al.. (2023). Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors. Clinical Cancer Research. 30(5). 942–958. 6 indexed citations
4.
Bazioli, Jaqueline Moraes, Daniel D. Lantvit, Samuel K. Kulp, et al.. (2023). Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models. Molecular Pharmaceutics. 20(6). 3049–3059. 3 indexed citations
5.
Chou, Chih-Chien, Kuen‐Haur Lee, I‐Lu Lai, et al.. (2014). AMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt–MDM2–Foxo3a Signaling Axis. Cancer Research. 74(17). 4783–4795. 147 indexed citations
6.
Huang, Po-Hsien, et al.. (2013). Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism. Biochemical and Biophysical Research Communications. 435(1). 107–112. 14 indexed citations
7.
Berman-Booty, Lisa D., Po‐Chen Chu, Jennifer M. Thomas‐Ahner, et al.. (2012). Suppression of Prostate Epithelial Proliferation and Intraprostatic Progrowth Signaling in Transgenic Mice by a New Energy Restriction-Mimetic Agent. Cancer Prevention Research. 6(3). 232–241. 8 indexed citations
8.
Bear, Misty D., et al.. (2012). Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC Veterinary Research. 8(1). 244–244. 18 indexed citations
9.
Huang, Po-Hsien, Po‐Chen Chu, Mei-Chuan Chen, et al.. (2011). Energy Restriction-mimetic Agents Induce Apoptosis in Prostate Cancer Cells in Part through Epigenetic Activation of KLF6 Tumor Suppressor Gene Expression. Journal of Biological Chemistry. 286(12). 9968–9976. 14 indexed citations
10.
Lin, Li, Brian Hutzen, Mingxin Zuo, et al.. (2010). Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells. Cancer Research. 70(6). 2445–2454. 197 indexed citations
11.
12.
Wei, Shuo, Samuel K. Kulp, & Ching‐Shih Chen. (2010). Energy Restriction as an Antitumor Target of Thiazolidinediones. Journal of Biological Chemistry. 285(13). 9780–9791. 65 indexed citations
13.
Chiu, Hao‐Chieh, Samuel K. Kulp, Shilpa Soni, et al.. (2009). Eradication of Intracellular Salmonella enterica Serovar Typhimurium with a Small-Molecule, Host Cell-Directed Agent. Antimicrobial Agents and Chemotherapy. 53(12). 5236–5244. 67 indexed citations
14.
Yang, Yating, et al.. (2009). A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer. IUScholarWorks (Indiana University). 1 indexed citations
15.
Sargeant, Aaron M., Samuel K. Kulp, Russell D. Klein, et al.. (2008). OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model. Cancer Research. 68(10). 3999–4009. 51 indexed citations
16.
Wang, Yu-Chieh, Samuel K. Kulp, Chih-Cheng Yang, et al.. (2008). Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors. Cancer Research. 68(8). 2820–2830. 52 indexed citations
17.
Lu, Yen‐Shen, Yoko Kashida, Samuel K. Kulp, et al.. (2007). Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology. 46(4). 1119–1130. 82 indexed citations
18.
Cheng, Hao, Zhongfa Liu, Samuel K. Kulp, et al.. (2006). Preclinical pharmacokinetic studies with s-HDAC-42 (NSC 736012), an inhibitor of histone deacetylase, by LC-MS/MS. Cancer Research. 66. 727–727. 2 indexed citations
19.
Porchia, Leonardo M., Marcy L. Guerra, Allan V. Espinosa, et al.. (2006). OSU03012, a novel PDK1 inhibitor, decreases thyroid cancer proliferation and migration via multiple downstream pathways.. Cancer Research. 66. 1205–1205. 1 indexed citations
20.
Zhu, Jiuxiang, Jui-Wen Huang, Ping‐Hui Tseng, et al.. (2004). From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors. Cancer Research. 64(12). 4309–4318. 215 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthias Ocker Breakdown of academic impact, for papers by A. Ivana Scovassi Breakdown of academic impact, for papers by Haiying Chen Breakdown of academic impact, for papers by Toshiaki Hayashi Breakdown of academic impact, for papers by Daniela Trisciuoglio Breakdown of academic impact, for papers by Ramzi M. Mohammad Breakdown of academic impact, for papers by Angela Nebbioso Breakdown of academic impact, for papers by Sibaji Sarkar Breakdown of academic impact, for papers by Xinliang Mao Breakdown of academic impact, for papers by William N. Hait
Rankless by CCL
2026